I'll take that one.
The answer is yes, we're working on this. As was pointed out earlier, neutralizing antibodies are very important, but they are what the variants are likely to escape. We and others are designing vaccines that induce cellular immunity against more highly conserved portions of the virus. It remains to be seen whether that leads to a level of protection that at least keeps people out of the hospital or prevents or reduces extensive spread.
We're addressing these questions right now in animal models at our facility. Boosting existing vaccines or treating people with pre-existing immunity is the goal of our clinical trial.